I'm LongbridgeAI, I can summarize articles.Revenue grew 25% and adjusted operating profit rose 18% year-over-year in H1 2026, driven by strong proprietary portfolio sales and successful launches. Upgraded 2026 guidance reflects continued momentum, with multiple late-stage pipeline assets advancing toward key readouts.Original document: Genmab A/S [GMAB] Slides Release — Aug. 6 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue grew 25% and adjusted operating profit rose 18% year-over-year in H1 2026, driven by strong proprietary portfolio sales and successful launches. Upgraded 2026 guidance reflects continued momentum, with multiple late-stage pipeline assets advancing toward key readouts.
Original document: Genmab A/S [GMAB] Slides Release — Aug. 6 2026